Bocobo AG, et al. - Researchers assessed if alpha-fetoprotein (AFP) changes during treatment are associated with outcomes in first-line (1L) sorafenib (SOR) therapy and any subsequent checkpoint inhibitors (CPI) in a US population (n=152). Patients who had received 1L SOR or SOR-based combination for advanced HCC, had ≥ 1 post-treatment AFP value available, and were enrolled on IRB-approved registry were included. Baseline AFP was < 20 in 43 patients and ≥ 400 in 59 patients. In this largest multicenter examination of AFP response to systemic therapy with SOR and CPI, there was no association of baseline AFP with time on treatment or overall survival (OS) for SOR or CPI. An inverse and significant association of AFP decrease and increase within the first 3 months of treatment with SOR and CPI, with median OS was observed.